Background: The aim is to describe the potential interactions between oral antineoplastic agents and concomitant medication. Previous studies proved that oral antineoplastic agents are associated with significant drug-drug interactions.

Methods: The retrospective observational study to detect the potential interactions drug between oral antineoplastic agents and concomitant medication. All drug interactions detected between concomitant medication and oral antineoplastic agents were recorded. All potential interactions were classified by database as C (monitor therapy), D (consider therapy modification) or X (avoid combination) risk level. The analysis was carried out with three different databases. A descriptive analysis was conducted, including into account the demographic and clinical data, as well as the drug most commonly prescribed in the analyzed treatment.

Results: A total de 315 drug-drug interactions were detected in 222 treatments. The average drug-drug interactions per patients relative to the total was 1,4. Most of the patients included had at least one potential interaction between oral antineoplastic agents and concomitant treatment. The interactions were resolved by monitoring or dose adjustment. Most part of interactions detected was of pharmacokinetic type (71.1%). For drug-drug interactions with antineoplastic agents, 180 interactions (57%) were classified as category C, 58 interactions (18.4%) as category D and 77 interactions (24.6%) as category X.

Conclusion: The study proved that oral antineoplastic agents can increase the risk of drug-drug interaction. The sensitivity observed when detecting an interaction is different between the databases consulted. It thus highlights the importance of determining the clinical relevance of oral chemotherapy drug-drug interactions. For this, multidisciplinary team’s participation is essential.

European Journal of Clinical Oncology Cancer poses a major challenge to development; it undermines socio-economic advances throughout the world. It is estimated that the number of patients with cancer would increase from 12.7 million in the year 2008 to 22.2 million by 2030. It is universally agreed that the condition is reaching epidemic proportions. At this time, the European Journal of Clinical Oncology is conveniently placed in the scholarly communication milieu to help counter the menace of cancer by aiding the development of novel treatment strategies, by providing novel insights into the mechanisms underlying this complex disease.

European Journal of Clinical Oncology publishes peer-reviewed original research articles, review articles, short communications, expert opinions, commentaries and letters/editorials based on open access policy. Author(s) are invited to submit their manuscripts as an e-mail attachment for fast and efficient processing. Aims & scope of the journal, key words, indexing as well as bibliographic information can be accessed at https://www.iomcworld.org/european-clinical-oncology.html

John Robert

Managing Editor
European Journal of Clinical Oncology
Mail ID: oncology@scholarlymed.com
WhatsApp no: + 1-504-608-2390